Regional Lymphotropic Therapy in Combination with Low Level Laser Therapy for Treating Multi-Drug-Resistant Tuberculosis

Abstract

With the growing incidence of Multi-Drug-Resistant Tuberculosis (MDR-TB) in newly identified patients, novel multimodality treatment methods are needed, aimed at reducing the time to sputum conversion and cavity healing, which would be applicable in MDR cases. Our experimental treatment consisted of the following: 1) chemotherapy based on the drug sensitivity profile, 2) local laser irradiation therapy for 25 days, and lymphotropic administration of isoniazid (to subcutaneous tissue in alternating locations: underarm area; fifth intercostal space along the sterna border; subclavian area where the first rib meets the sternum) in a daily dose of 10mg/kg 5 times a week. This treatment was significantly more effective in newly detected destructive MDR-TB versus the standard Category IV regimen for MDR-TB in terms of reduced time for sputum culture conversion and cavity healing, estimated to be 6 months after initiation of treatment. (Int J Biomed. 2016; 6(1):82-84.).

2 Figures and Tables

Cite this paper

@inproceedings{Dogorova2016RegionalLT, title={Regional Lymphotropic Therapy in Combination with Low Level Laser Therapy for Treating Multi-Drug-Resistant Tuberculosis}, author={Oksana Dogorova and Ekaterina Pavlova}, year={2016} }